Impact of [11C]Methionine Positron Emission Tomography for Target Definition of Glioblastoma Multiforme in Radiation Therapy Planning

Matsuo, Masayuki; Miwa, Kazuhiro; Tanaka, Osamu; Shinoda, Jun; Nishibori, Hironori; Tsuge, Yusuke; Yano, Hirohito; Iwama, Toru; Hayashi, Shinya; Hoshi, Hiroaki; Yamada, Jitsuhiro; Kanematsu, Masayuki; Aoyama, Hidefumi

doi:10.1016/j.ijrobp.2010.09.020

Cited by 62 publications

(37 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As in most cases, the latter combines areas of both MRI features, the brain volume remains feasible to treat based on this biological information. 70,71 It was shown that the MET-PETpositive volumes are correlated with outcome in photon and in carbon ion radiotherapy. 72,73 In both studies, pre-treatment MET-PET was performed but not used for target volume delineation.…”

Section: Imaging Implications In Neurosurgerymentioning

confidence: 99%

Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs

Neubeck¹,

Seidlitz²,

Kitzler³

et al. 2015

BJR

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults. The standard therapy for GBM is maximal surgical resection followed by radiotherapy with concurrent and adjuvant temozolomide (TMZ). In spite of the extensive treatment, the disease is associated with poor clinical outcome. Further intensification of the standard treatment is limited by the infiltrating growth of the GBM in normal brain areas, the expected neurological toxicities with radiation doses .60 Gy and the dose-limiting toxicities induced by systemic therapy. To improve the outcome of patients with GBM, alternative treatment modalities which add low or no additional toxicities to the standard treatment are needed. Many Phase II trials on new chemotherapeutics or targeted drugs have indicated potential efficacy but failed to improve the overall or progression-free survival in Phase III clinical trials. In this review, we will discuss contemporary issues related to recent technical developments and new metabolic strategies for patients with GBM including MR (spectroscopy) imaging, (amino acid) positron emission tomography (PET), amino acid PET, surgery, radiogenomics, particle therapy, radioimmunotherapy and diets.

show abstract

Section: Imaging Implications In Neurosurgerymentioning

confidence: 99%

Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs

Neubeck¹,

Seidlitz²,

Kitzler³

et al. 2015

BJR

View full text Add to dashboard Cite

show abstract

“…Several probes for this target have been developed. These include clinically approved IgG molecules (about 150 kDa) such as 89 Zr-trastuzumab [37,104], antibody fragments including 68 Ga-DOTA-HER2 F(ab')2-trastuzumab [105], and much smaller Affibodies (about 6.5 kDa) including 18 F-GE-226 for PET [106] and 111 In-ABY-025 for analogous single photon imaging [107]. The long time to achieve contrast (4-5 days) due to the slow pharmacokinetics of IgGs and a requirement for titrating the optimal dose of the tracer in drugnaive patients are limitations of the antibody approach.…”

Section: Imaging Proliferation Growth and Replicative Immortalitymentioning

confidence: 99%

“…Imaging of angiogenesis growth factors and interaction with their cognate receptors, e.g. VEGF and VEGFR, has been undertaken preclinically with 64 Cu-DOTA-VEGF and clinically with 89 Zr-bevacizumab immunoPET [40] (Table 1). However, most activity in the field relates to detection of α v β 3 and α v β 5 integrin receptors, factors overexpressed in tumour vasculature compared to mature vessels.…”

Section: Imaging Tumour Angiogenesismentioning

confidence: 99%

Radiopharmaceuticals as probes to characterize tumour tissue

Alam

Arshad

Nguyen

et al. 2015

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Tumour cells exhibit several properties that allow them to grow and divide. A number of these properties are detectable by nuclear imaging methods. We discuss crucial tumour properties that can be described by current radioprobe technologies, further discuss areas of emerging radioprobe development, and finally articulate need areas that our field should aspire to develop. The review focuses largely on positron emission tomography and draws upon the seminal 'Hallmarks of Cancer' review article by Hanahan and Weinberg in 2011 placing into context the present and future roles of radiotracer imaging in characterizing tumours.

show abstract

“…All methods provided 11 C methionine according to the pharmaceutical regulation and established imaging with 11 C methionine as a gold standard for visualization of glicomas in neurooncology [3,12,13] and supplementary in adenocarcinoma [14] or in radiation therapy planning [15]. 11 C acetate is an important endogenous substrate in the Krebs cycle and takes part in metabolism of fatty acids and cholesterols.…”

Section: Endogenous Compoundsmentioning

confidence: 99%

Synthesis of Endogenous Compounds Labeled with¹¹C for Positron Emission Tomography

Kilian¹,

Pękal²

2015

Acta Phys. Pol. A

View full text Add to dashboard Cite

Among the β + emitting isotopes, produced in medical cyclotrons, carbon-11 is promising radionuclide for labeling of biologically active compounds and tracking their distribution in living organism. Therefore aminoacids, carboxylic acids, fatty acids and amines have been widely used in assessing and staging of brain tumors ( 11 Cmethionine), prostate cancer ( 11 C-choline, 11 C-acetate) and neurological disorders ( 11 C-labeled neurotransmitters). This paper reviews recent achievements in synthesis of endogenous substances labeled with 11 C and presents our experience in 11 C-methionine synthesis. Proposed protocol is a reliable tool for routine manufacturing in clinical applications and animal studies.

show abstract

Impact of [11C]Methionine Positron Emission Tomography for Target Definition of Glioblastoma Multiforme in Radiation Therapy Planning

Cited by 62 publications

References 25 publications

Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs

Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs

Radiopharmaceuticals as probes to characterize tumour tissue

Synthesis of Endogenous Compounds Labeled with¹¹C for Positron Emission Tomography

Contact Info

Product

Resources

About

Impact of [11C]Methionine Positron Emission Tomography for Target Definition of Glioblastoma Multiforme in Radiation Therapy Planning

Cited by 62 publications

References 25 publications

Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs

Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs

Radiopharmaceuticals as probes to characterize tumour tissue

Synthesis of Endogenous Compounds Labeled with11C for Positron Emission Tomography

Contact Info

Product

Resources

About

Synthesis of Endogenous Compounds Labeled with¹¹C for Positron Emission Tomography